Patents by Inventor Annemieke M. De Jong

Annemieke M. De Jong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10253073
    Abstract: Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: April 9, 2019
    Assignee: Academisch Ziekenhuis Leiden
    Inventors: Sjoerd Hendrikus Van Der Burg, Tom H. M. Ottenhoff, Annemieke Geluk, Maria Johanna Philomena Schoenmaekers-Welters, Annemieke M. De Jong, Rienk Offringa, Cornelis Johannes Maria Melief, Reinaldus Everardus Maria Toes
  • Publication number: 20170320915
    Abstract: Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 9, 2017
    Applicant: Academisch Ziekenhuis Leiden
    Inventors: Sjoerd Hendrikus VAN DER BURG, Tom H. M. OTTENHOFF, Annemieke GELUK, Maria Johanna Philomena SCHOENMAEKERS-WELTERS, Annemieke M. DE JONG, Rienk OFFRINGA, Cornelis Johannes Maria MELIEF, Reinaldus Everardus Maria TOES
  • Patent number: 9650423
    Abstract: Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: May 16, 2017
    Assignee: Academisch Ziekenhuis Leiden
    Inventors: Sjoerd Hendrikus Van Der Burg, Tom H. M. Ottenhoff, Annemieke Geluk, Maria Johanna Philomena Schoenmaekers-Welters, Annemieke M. De Jong, Rienk Offringa, Cornelis Johannes Maria Melief, Reinaldus Everardus Maria Toes
  • Publication number: 20150343053
    Abstract: Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.
    Type: Application
    Filed: August 21, 2015
    Publication date: December 3, 2015
    Applicant: ACADEMISCH ZIEKENHUIS LEIDEN
    Inventors: Sjoerd Hendrikus VAN DER BURG, Tom H. M. OTTENHOFF, Annemieke GELUK, Maria Johanna Philomena SCHOENMAEKERS-WELTERS, Annemieke M. DE JONG, Rienk OFFRINGA, Cornelis Johannes Maria MELIEF, Rene Everardus Maria TOES
  • Patent number: 9115185
    Abstract: The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: August 25, 2015
    Assignee: Academisch Ziekenhuis Leiden
    Inventors: Sjoerd Hendrikus Van Der Burg, Tom H. M. Ottenhoff, Annemieke Geluk, Maria Johanna Philomena Schoenmaekers-Welters, Annemieke M. De Jong, Rienk Offringa, Cornelis Johannes Maria Melief, Rene Everardus Maria Toes
  • Patent number: 7202034
    Abstract: The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22–45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22–35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22–35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22–35 amino acid long peptides.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: April 10, 2007
    Assignee: Academisch Ziekenhuis Leiden
    Inventors: Sjoerd Hendrikus Van Der Burg, Tom H. M. Ottenhorf, Annemieke Geluk, Maria Johanna Philomena Schoenmaekers-Welters, Annemieke M. De Jong, Rienk Offringa, Cornelis Johannes Maria Melief, Rene Everardus Maria Toes
  • Publication number: 20040081658
    Abstract: The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.
    Type: Application
    Filed: November 12, 2003
    Publication date: April 29, 2004
    Inventors: Sjoerd Hendrikus Van Der Burg, Tom H. M. Ottenhorf, Annemieke Geluk, Maria Johanna Philomena Schoenmaekers-Welters, Annemieke M. De Jong, Rienk Offringa, Rene Everardus Maria Toes